Oppenheimer Maintains an “Outperform Rating” on Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On April 30, Oppenheimer raised its price target on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) from $104 to $111.  It maintained an “Outperform” rating on the stock while noting shares rose after first-quarter results and updated guidance.

On April 29, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported first-quarter 2026 results. Growing demand for TRYNGOLZA is driven by launch execution while raising full-year revenue guidance.

The company said the FDA accepted the olezarsen sNDA for priority review, with launch preparations for severe hypertriglyceridemia progressing, while growing peak net sales guidance for TRYNGOLZA to over $3 billion.

Oppenheimer Maintains an “Outperform Rating” on Pharmaceuticals, Inc. (IONS)

The pipeline advanced. The firm said the FDA accepted the “zilganersen NDA” for priority review, positioning its first independent neurology launch.

CEO Brett Monia summed it up simply by stating that the business is performing well on both the commercial and R&D fronts. He noted future Phase 3 readouts and launches for olezarsen and zilganersen this year.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a firm that develops and markets human therapeutic drugs using antisense technology. It is based in Carlsbad, California.

While we acknowledge the risk and potential of IONS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IONS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.